Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spanish Registry of RYR1 and CACNA1S Polymorphisms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03964870
Recruitment Status : Active, not recruiting
First Posted : May 28, 2019
Last Update Posted : May 29, 2019
Sponsor:
Information provided by (Responsible Party):
Oscar Diaz-Cambronero, Hospital Universitario La Fe

Brief Summary:

Study design: The Spanish registry of RYR1 and CACNA1S polymorphisms (RYCA) is an anonymous descriptive observational multicentre study that aims to identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population. Secondarily, its correlation with the binding mutations described in both genes at European level by the EMHG will be evaluated to assess the incidence of malignant hyperthermia in Spain. The RYCA registry complies with the highest standards of European and international homologation, both with regard to computer security and the protection of personal data (Data Protection Law 15/1999).

Hypothesis: Performing a Spanish registry of RYR1 and CACNA1S polymorphisms will contribute to describe the variants present in our environment and determine their relationship with MH susceptibility.

Objectives:

  • Describe the national polymorphisms of the RYR1 and CACNA1S genes
  • To evaluate the incidence of genetic MH susceptibility according to the recommendations of the EMHG.

The presence of polymorphisms in a population that has not been studied before may have a difficult correlation with the mutations described in the EMHG webpage.

Eligibility Criteria: The sample contained in the registry will originate from the genetic data of patients unrelated to HM who have been sequenced the RYR1 and CACNA1S gene by another pathology. The data related to the genetic analysis will be provided without identifying data of the patient or the clinical history. There will be no possibility of identification of the patient by the team responsible for the RYCA registry, so the request for informed consent is not viable. There will be no selection of participants or patient follow-up.

Methodology: A preliminary pilot study will be conducted in an unselected anonymous cohort of the sequenced exome database of the RYR1 and CACNA1S gene at the La Fe Health Research Institute (IISlaFe). The population contained in this database is random and unrelated to HM and the patients are anonymous, so we do not have access to personal data or medical history. If the analysis is feasible, a request for collaboration will be transferred to the Genetics Services / Research Units with experience in the exome sequencing of the RYR1 and CACNA1S genes. Anonymous readings will be requested to carry out the registration and description of the variants existing in the Spanish population and their relationship with the variants described by the EMHG.

Variables: The registry will include the chromosomal coordinates, number of total patients included, number of patients whose variant is in heterozygosis, number of patients whose variant is in homozygosis and allelic frequency. Thus, for each of the genes of interest, and making use of their respective chromosomal coordinates, information regarding the variants that these might include will be extracted.

Sample size. Sample size calculation is not considered since it is a descriptive record.


Condition or disease Intervention/treatment
Malignant Hyperthermia Polymorphisms in Genes RYR1 and CACNAS1S Diagnostic Test: Diagnostic of polymorphisms in malignant hyperthermia

Layout table for study information
Study Type : Observational
Estimated Enrollment : 5000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Spanish Registry of RYR1 and CACNA1S Polymorphisms in Unselected Population for Evaluation of Malignant Hyperthermia Susceptibility (MHS). RYCA Registration
Actual Study Start Date : December 5, 2018
Estimated Primary Completion Date : November 5, 2020
Estimated Study Completion Date : December 5, 2020



Intervention Details:
  • Diagnostic Test: Diagnostic of polymorphisms in malignant hyperthermia
    Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.


Primary Outcome Measures :
  1. Describe the national polymorphisms of the RYR1 and CACNA1S genes [ Time Frame: Day 1 ]

    The peripheral blood must be extracted by venous puncture. For this, it is necessary to carry out the extraction of the blood by qualified health personnel respecting the corresponding hygienic-sanitary norms. The blood must be in a tube with EDTA anticoagulant (preferably). The method of extraction of peripheral blood DNA: is carried out mainly by automatic procedure using the QIASYMPHONY SP DNA extractor-purifying equipment and the QYASIM DNA MIDI KIT Kit (Qiagen), Cat. No: 931255, following the manufacturer's protocols.

    The DNA extraction stage is collected in the GESTLAB system as SAMPLE PROCESSING (it comprises extraction and quantification via Nanodrop, as indicated below).


  2. To evaluate the incidence of genetic MH susceptibility according to the recommendations of the EMHG. [ Time Frame: Day 1 ]

    The peripheral blood must be extracted by venous puncture. For this, it is necessary to carry out the extraction of the blood by qualified health personnel respecting the corresponding hygienic-sanitary norms. The blood must be in a tube with EDTA anticoagulant (preferably). The method of extraction of peripheral blood DNA: is carried out mainly by automatic procedure using the QIASYMPHONY SP DNA extractor-purifying equipment and the QYASIM DNA MIDI KIT Kit (Qiagen), Cat. No: 931255, following the manufacturer's protocols.

    The DNA extraction stage is collected in the GESTLAB system as SAMPLE PROCESSING (it comprises extraction and quantification via Nanodrop, as indicated below).



Biospecimen Retention:   Samples With DNA
Blood samples to identify genes RYR1 and CACNAS1S


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Inclusion Criteria: Patents with malignant hyperthermia which genes RYR1 and CACNA1S have been sequenced for another pathology
Criteria
The sample contained in the registry will originate from the genetic data of patients unrelated to malignant hyperthermia who have been sequenced the RYR1 and CACNA1S gene by another pathology. The data related to the genetic analysis will be provided without identifying data of the patient or the clinical history. There will be no possibility of identification of the patient by the team responsible for the RYCA registry, so the request for informed consent is not viable. There will be no selection of participants or patient follow-up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03964870


Locations
Layout table for location information
Spain
IIS la Fe
Valencia, Spain, 46026
Sponsors and Collaborators
Hospital Universitario La Fe
Layout table for additonal information
Responsible Party: Oscar Diaz-Cambronero, Principal Investigator of Anesthesiology, Hospital Universitario La Fe
ClinicalTrials.gov Identifier: NCT03964870    
Other Study ID Numbers: RYCA
First Posted: May 28, 2019    Key Record Dates
Last Update Posted: May 29, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Oscar Diaz-Cambronero, Hospital Universitario La Fe:
Malignant Hyperthermia
Additional relevant MeSH terms:
Layout table for MeSH terms
Fever
Malignant Hyperthermia
Body Temperature Changes
Intraoperative Complications
Pathologic Processes
Postoperative Complications